Name: Guo Yanchuan
He currently serves as researcher, Head of Gelatin and Micro/Nano Carbon Materials Research Institute, Technical Institute of Physics and Chemistry, Chinese Academy of Sciences, Vice Director of Biomaterials and Applied Technology Research Center, Director of Chinese Academy of Sciences-Dongbao Bio-Calc and Collagen Engineering Application Research Center, a member of China Light Industry Association Gelatin Branch, Director of the Science and Technology Commission, Deputy Secretary-General, Associate Editor of The Science and Technology of Gelatin.
In 2010, he received his Ph.D. degree from the Technical Institute of Physics and Chemistry of the Chinese Academy of Sciences. From 2010 to 2011, he worked as a visiting scholar at the UCLA School of Basic Medicine in molecular biology research. From 2012 to 2014, he went to the University of Uppsala in Sweden for collaborative research. He has published more than 40 papers and applied for 25 Chinese patents, including 7 authorizations and 2 US patents.
Application of enzymatic hydrolysis technology in the production of biological products such as gelatin and chitosan; application of gelatin and collagen peptides in health and medical fields; preparation of bioceramics and research in the field of bone repair.
1) Junli Liu，Yanchuan Guo*,Bovine collagen peptides compounds promote the proliferation and differentiation of MC3T3-E1 pre-osteoblasts，PLOS ONE,2014.
2) Ming Ma,Yanchuan Guo*,Preparation, thermal stability and biocompatibility studies of gelatin-induced hydroxyapatite co-substituted with essential physiological trace elements, CHINESE SCIENCE BULLETIN (2014)59(7):606-615
3) Wei Peng, Yanchuan Guo*, Comprehensive Analysis on elements, energy recovery, and oil composition of biomass deoxy-liquefaction, ENERGY FUELS 2013,27,2157-2166
4) (Patent) Gelatin and Calcium Phosphate Composite Porous Microspheres for Bone Repair and Their Preparation and Pathway, Authorized by the Intellectual Property Office of China, 2012.11.14
5）Jiabin An, Yanchuan Guo, Mathew Rettig*,Therapeutics, Targets, and Chemical Biology: Hyperactivated JNK Is a Therapeutic Target in pVHL-Deficient Renal Cell Carcinoma. Cancer Research.2013 73:4 1374-1385